Article Text

Download PDFPDF

Zoledronate treatment in active Paget’s disease
  1. G Chung1,
  2. R W Keen1,2
  1. 1Metabolic Unit, Royal National Orthopaedic Hospital, Brockley Hill, Stanmore, Middlesex HA7 4LP, UK
  2. 2Bone and Mineral Centre, Department of Medicine, University College London, London WC1E 6JJ, UK
  1. Correspondence to:
    Dr G Chung;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Bisphosphonates are analogues of pyrophosphate that suppress bone remodelling through inhibition of osteoclast mediated bone resorption and are widely used in the management of various metabolic bone conditions: osteoporosis, Paget’s disease, and hypercalcaemia of malignancy. Lately there has been increasing interest in the new third generation bisphosphonate, zoledronate, which is currently the most potent of its class available (10 000 times more potent than etidronate and 100 times more than pamidronate1). Zoledronate appears to be better than pamidronate in the treatment of cancer related hypercalcaemia,2 and a recent study in postmenopausal women with low bone mineral density (BMD) demonstrated improvements in BMD and suppression of bone turnover lasting for up to one year after a single 4 mg infusion.3 We now wish to report a case of the use of zoledronate in active Paget’s disease.


A 64 year old West Indian man with a 14 year history of polyostotic Paget’s disease (sites affected: skull, mandible, thoracolumbar spine, sacrum, pelvis, and left femur) was being regularly reviewed in the metabolic bone clinic. He had previously been treated at various times with injectable calcitonin (for six months), etidronate (for six months), tiludronate (for three months) and pamidronate (three courses: total doses 120, 60, and 240 mg), achieving variable symptomatic and biochemical responses. Recently his disease progressed and despite two further courses of intravenous pamidronate (total doses 120 mg and 180 mg) there was no major reduction of serum alkaline phosphatase (fig 1). Biochemical activity continued to rise and he began to complain of facial pain. On clinical examination there was no neurological deficit. He was given a single infusion of intravenous zoledronate 4 mg. There were no acute reactions or complications and calcium levels and renal function after infusion remained normal. His symptoms improved over eight weeks and over a period of six months the alkaline phosphatase normalised, falling from 569 to 85 U/l (normal 30–130) (fig 1).

Figure 1

Serum alkaline phosphatase levels over a period of five years. Normal range 30–130 U/l. Timing of bisphosphonate treatment shown by arrows.


Paget’s disease is the second commonest metabolic bone disease in the UK, affecting 2% of the population above the age of 55 years.4 The condition is characterised by focal increases in bone remodelling that can affect one or multiple sites. Active disease with symptoms indicates need for treatment, although patients with lesions at problematic sites (weightbearing bones, skull, spine, or bones around joints) should also be considered for antiresorptive treatment in the absence of symptoms, to prevent future complications.5 Bisphosphonates are regarded as the preferred treatment and short term studies have shown that they improve bone pain and biochemical markers of bone turnover in Paget’s disease. Secondary resistance to bisphosphonates, after repeated courses of treatment, has been seen with etidronate6 and, more recently, with pamidronate.7 This acquired resistance to one bisphosphonate, demonstrated by a blunted alkaline phosphatase response or shorter remission duration, can usually be overcome by using a different bisphosphonate.7

With a single infusion of zoledronate we were able to achieve clinical and biochemical remission in our patient with active Paget’s disease who had become resistant to pamidronate. Previous dose ranging studies, one of which was placebo controlled, have shown that single infusions of microgram amounts of zoledronate (up to 400 μg) inhibit bone resorption in patients with active Paget’s disease8,9 and, in addition, no detectable impairment of bone mineralisation has been found.10 The results of further studies examining the use of zoledronate in patients with metabolic bone disease are awaited with interest.